Literature DB >> 22875968

A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential.

Kai Deng1, M Christine Zink, Janice E Clements, Robert F Siliciano.   

Abstract

Simian immunodeficiency virus (SIV) infection in macaques is so far the best animal model for human immunodeficiency virus type 1 (HIV-1) studies, but suppressing viral replication in infected animals remains challenging. Using a novel single-round infectivity assay, we quantitated the antiviral activities of antiretroviral drugs against SIV. Our results emphasize the importance of the dose-response curve slope in determining the inhibitory potential of antiretroviral drugs and provide useful information for regimen selection in treating SIV-infected animals in models of therapy and virus eradication.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22875968      PMCID： PMC3457139          DOI： 10.1128/JVI.01563-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  38 in total

1.  Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies.

Authors:  Dongsheng Zhang; Akikazu Murakami; R Paul Johnson; Jianhua Sui; Jihua Cheng; Jirong Bai; Wayne A Marasco
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  HIV drug resistance.

Authors:  François Clavel; Allan J Hance
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  Re-emergence of HIV after stopping therapy.

Authors:  T W Chun; R T Davey; D Engel; H C Lane; A S Fauci
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

5.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

6.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

7.  The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.

Authors:  C B Buck; X Shen; M A Egan; T C Pierson; C M Walker; R F Siliciano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.

Authors:  Anding Shen; M Christine Zink; Joseph L Mankowski; Karen Chadwick; Joseph B Margolick; Lucy M Carruth; Ming Li; Janice E Clements; Robert F Siliciano
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.

Authors:  Z Hel; D Venzon; M Poudyal; W P Tsai; L Giuliani; R Woodward; C Chougnet; G Shearer; J D Altman; D Watkins; N Bischofberger; A Abimiku; P Markham; J Tartaglia; G Franchini
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

10.  Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

Authors:  Ronald S Veazey; Per Johan Klasse; Thomas J Ketas; Jacqueline D Reeves; Michael Piatak; Kevin Kunstman; Shawn E Kuhmann; Preston A Marx; Jeffrey D Lifson; Jason Dufour; Megan Mefford; Ivona Pandrea; Steven M Wolinsky; Robert W Doms; Julie A DeMartino; Salvatore J Siciliano; Kathy Lyons; Martin S Springer; John P Moore
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307
View more
  4 in total

1.  The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.

Authors:  Shuai Chang; Daomin Zhuang; Wei Guo; Lin Li; Wenfu Zhang; Siyang Liu; Hanping Li; Yongjian Liu; Zuoyi Bao; Jingwan Han; Hongbin Song; Jingyun Li
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

Review 2.  Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

3.  Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.

Authors:  Y Xu; Y F Li; D Zhang; M Dockendorf; E Tetteh; M L Rizk; J A Grobler; M-T Lai; J Gobburu; W Ankrom
Journal:  Clin Transl Sci       Date:  2016-05-12       Impact factor: 4.689

4.  Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach.

Authors:  Joshua T Schiffer; Dave A Swan; Daniel Stone; Keith R Jerome
Journal:  PLoS Comput Biol       Date:  2013-07-04       Impact factor: 4.475
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.